Clinical Trials Logo

Clinical Trial Summary

This study is a single-center, randomized, single‑blind, placebo (PBO)-controlled, multiple-dose study to characterize the safety, tolerability, PK, and PD of IV BNZ-1 administered to healthy adult subjects once weekly (QW) for 4 doses or once every other week (QOW) for 3 doses. Five cohorts of 6 subjects randomized 5 BNZ-1:1 PBO are planned to be enrolled in the trial. Participants will be followed for 4 weeks after the last dose for safety monitoring, and collection of PK and PD samples.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Safety and Tolerability in Healthy Subjects

NCT number NCT03239379
Study type Interventional
Source Bioniz Therapeutics
Contact
Status Completed
Phase Phase 1
Start date October 30, 2017
Completion date March 8, 2018